论文部分内容阅读
新制癌素(Neocarzinostatin)是早在1957年从放线菌Strep.carzinostaticus的培养滤液中分离、精制而得的抗癌抗菌素,为一种分子量约9,000,由109个氨基酸组成的单链酸性多肽。根据新制癌素在动物的体内分布,曾试用于胃癌、胰癌、皮肤癌及膀胱癌等实体肿瘤,但临床效果并不满意。作者初次尝试应用新制癌素作为急性白血病的诱导缓解药,结果表明,新制癌素具有明显的抗白血病作用,且对正常造血系统的抑制以及其它副作用均极低。对14例急性白血病患者,单独用新制癌素进行缓解治疗,其中粒细胞性白血病
Neocarzinostatin is an anticancer antibiotic that was isolated and purified from the culture filtrate of actinomycete Strep. carzinostaticus as early as 1957 and is a single-chain acidic polypeptide consisting of 109 amino acids with a molecular weight of about 9,000. According to the distribution of neocarcinoma in animals, it has been tried for solid tumors such as gastric cancer, pancreatic cancer, skin cancer, and bladder cancer, but the clinical effect is not satisfactory. The authors first attempted to use new melanogenesis as an inducer of acute leukemia. The results showed that the new melanoma has obvious anti-leukemia effect, and the inhibition of normal hematopoietic system and other side effects are extremely low. 14 patients with acute leukemia were treated with neoadjuvant alone, including myelocytic leukemia